ImmunoGen Announces Recent Product Program Advancements and Anticipated 2016 Events in Advance of J.P. Morgan Healthcare Conference

ImmunoGen, Inc. IMGN today announced recent product program advancements and anticipated 2016 events in advance of the 34th Annual J.P. Morgan Healthcare Conference. "ImmunoGen made significant progress in 2015 that is anticipated to lead to a number of meaningful events in 2016 and beyond," commented Daniel Junius, President and CEO. "For mirvetuximab soravtansine, our lead program, these include completing patient enrollment in three disease-specific cohorts that can provide informative data in 2016. They also include putting in place the FORWARD I trial intended to support an Accelerated Approval pathway as well as the FORWARD II combination See full press release